Inborn errors of mitochondrial fatty acid oxidation

Critical Reviews in Clinical Laboratory Sciences

Volumn 37, Issue 1, 2000, Pages 1-44

  Bennett, Michael J ^a   Rinaldo, Piero ^b   Strauss, Arnold W ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Energy metabolism; Liver disease; Liver disease of pregnancy; Skeletal myopathy; Sudden infant death

Indexed keywords

CARNITINE; FATTY ACID; KETONE BODY;

ENERGY METABOLISM; FATTY ACID OXIDATION; HEART MUSCLE; HUMAN; INBORN ERROR OF METABOLISM; LIVER; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE;

EID: 0034068083     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360091174169     Document Type: Review

References (168)

1. 1. Roe CR, Coates PM. Mitochondrial fatty acid oxidation disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 7th ed. Pp. 1501-33. New York: McGraw-Hill, 1995.
2. 2. Hale DE, Bennett MJ. Fatty acid oxidation disorders: a new class of metabolic diseases. J Pediatr 1992; 121: 1-11.
3. 3. Schulz H. Mitochondrial β-oxidation. In: Tanaka K, Coates PM, eds. Fatty acid oxidation: clinical, biochemical and molecular aspects. Pp. 23-36. New York: Alan R. Liss, 1990.
4. 4. Stanley CA. Disorders of fatty acid oxidation. In: Fernandes J, Saudubray J-M, van den Berghe G, eds. Inborn metabolic diseases: diagnosis and treatment, 2nd ed. Pp. 133-43, 1995.
5. 5. Coates PM. New developments in the diagnosis and investigation of mitochondrial fatty acid oxidation disorders. Eur J Pediatr 1994; 153 [suppl 1]: 49-56.
6. 6. Eaton S, Bartlett KM Pourfarzam M. Mammalian mitochondrial β-oxidation. Biochem J 1996; 320: 345-57.
7. 7. Saudubray J-M, Martin D, Poggi-Travert, et al. Clinical presentations of inherited mitochondrial fatty acid oxidation disorders: an update. Int Pediatr 1997; 12: 34-40.
8. 8. Bennett MJ. Fatty acid oxidation: normal metabolism and genetic disease. Diag Endo Metab 1997; 15: 11-23.
9. 9. Rinaldo P, Raymond K, Al-Odaib A, et al. Clinical and biochemical features of fatty acid oxidation disorders. Curr Opin Pediatr 1998; 10: 615-21.
10. 10. Schaffer JE, Lodish HF. Molecular mechanism of long-chain fatty acid uptake. Trends Cardiovasc Med 1995; 5: 218-24.
11. 11. Bremer J. Carnitine: metabolism and functions. Physiol Rev 1983; 63: 1420-80.
12. 12. Rebouche CJ, Mack DL. Sodium gradient-stimulated transport of L-carnitine into renal brush border membrane vesicles: kinetics, specificity, and regulation by dietary carnitine. Arch Biochem Biophys 1984; 235: 393-402.
13. 13. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 1997; 244: 1-14.
14. 14. Frerman FE, Goodman SI. Nuclear-encoded defects of the mitochondrial respiratory chain, including glutaric acidemia type II. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 7th ed. Pp. 1611-29. New York: McGraw-Hill, 1995.
15. 15. Schaffer JE, Lodish HF. Expression, cloning and characterization of a novel adipocyte fatty acid binding protein. Cell 1994; 79: 427-36.
16. 16. Stemmel W, Strohmeyer G, Borchard F, et al. Isolation and characterization of fatty acid binding protein in rat liver membranes. Proc Natl Acad Sci USA 1985; 82: 4-8.
17. 17. Fuji S, Kawaguchi H, Yasuda H. Isolation and partial characterization of an amphiphilic 56-kDa fatty acid binding protein from rat renal basolateral membrane. J Biochem Biophys Res 1987; 101: 679-84.
18. 18. Trigatti BL, Mangaroo D Gerber GE. Photoaffinity labelling and fatty acid permeation in 3&3-L1 adipocytes. J Biol Chem 1991; 266: 22621-5.
19. 19. Abumrad NA, Raafat El-Maghrabi M, Ameri EZ, et al. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. J Biol Chem 1993; 268: 17665-8.
20. 20. Hirsch D, Stahl A, Lodish HF. A family of fatty acid transporters conserved from mycobacterium to man. Proc Natl Acad Sci USA 1998; 95: 8625-9.
21. 21. Tein I, Bukovac SW, Xie ZW. Characterization of the human plasmalemmal carnitine transporter in cultured skin fibroblasts. Arch Biochem Biophys 1996; 329: 145-55.
22. 22. Lamhonwah A-M, Tein I. Carnitine uptake defect: frameshift mutations in the human plasmalemmal carnitine transporter gene. Biochem Biophys Res Commun 1998; 252: 396-401.
23. 23. Nezu J-I, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nature Genet 1999; 21: 91-4.
24. 24. Britton CH, Schultz RA, Zhang B, et al. Human liver mitochondrial carnitine palmitoyltransferase I: characterization of its cDNA and chromosomal localization and partial analysis of the gene. Proc Natl Acad Sci USA 1995; 92: 1984-8.
25. 25. Britton CH, Mackay DW, Esser V, et al. Fine chromosome mapping of the genes for human liver and muscle carnitine palmitoyltransferase I (CPT IA and CPT IB). Genomics 1997; 40: 209-11.
26. 26. McGarry JD. Ketogenesis and lipogenesis: metabolic integration in health and disease. Biochem Soc Trans 1995; 23: 481-5.
27. 27. Huizing M, Iacobazzi V, IJlst L, et al. Cloning of the human carnitine-acylcarnitine carrier cDNA and identification of the molecular defect in a patient. Am J Hum Genet 1997; 61: 1239-45.
28. 28. Indiveri C, Iacobazzi V, Giangregorio N, et al. The mitochondrial carnitine carrier protein: cDNA cloning, primary structure and comparison with other mitochondrial transport proteins. Biochem J 1997; 321: 713-9.
29. 29. Finocchiaro G, Taroni F, Rocchi M, et al. cDNA cloning, sequence analysis, and chromosomal localization of the gene for human carnitine palmitoyltransferase. Proc Natl Acad Sci USA 1991; 88: 661-5 (erratum: 88: 981).
30. 30. Demaugre F, Bonnefont JP, Cepanec C, et al. Immunoquantitative analysis of human carnitine palmitoyltransferase I and II defects. Pediatr Res 1990; 27: 497-500.
31. 31. Izai K, Uchida Y, Orii T, et al. Novel fatty acid β-oxidation enzymes in rat liver mitochondria. I. Purification and properties of very-long-chain acyl coenzyme A dehydrogenase. J Biol Chem 1992; 267: 1027-33.
32. 32. Andresen BS, Bross P, Vianey-Saban C, et al. Cloning and characterization of human very-long-chain acyl-CoA dehydrogenase cDNA, chromosomal assignment of the gene and identification in four patients of nine different mutations within the VLCAD gene. Hum Mol Genet 1996; 5: 461-72.
33. 33. Uchida Y, Izai K, Orii T, et al. Novel fatty acid β-oxidation enzymes in rat liver mitochondria. II: Purification and properties of enoyl-CoA hydratase/ 3-hydroxyacyl-CoA dehydrogenase/ 3-ketoacyl-CoA thiolase trifunctional protein. J Biol Chem 1992; 267: 1034-41.
34. 34. Carpenter K, Pollitt RJ, Middleton B. Human long-chain 3-hydroxyacyl-CoA dehydrogenase is a multifunctional membrane-bound β-oxidation enzyme of mitochondria. Biochem Biophys Res Commun 1992; 183: 443-8.
35. 35. Ushikubo S, Aoyama T, Kamijo T, et al. Molecular characterization of mitochondrial trifunctional protein deficiency: formation of the enzyme complex is important for stabilization of both alpha and beta subunits. Am J Hum Genet 1996; 58: 979-88.
36. 36. Weinberger MJ, Rinaldo P, Strauss AW, et al. Intact α-subunit is required for membrane-binding of human mitochondrial trifunctional β-oxidation protein, but is not necessary for conferring 3-ketoacyl-CoA thiolase activity to the β-subunit. Biochem Biophys Res Commun 1995; 209: 47-52.
37. 37. IJlst L, Ruiter JPN, Hoovers JMN, et al. Common missense mutation G1528C in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency-characterization and expression of the mutant protein, mutation analysis on genomic DNA and chromosomal localization of the mitochondrial trifunctional protein alpha subunit gene. J Clin Invest 1996; 98: 1028-33.
38. 38. Sims HF, Brackett JC, Powell CK, et al. The molecular basis of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci USA 1995; 92: 841-5.
39. 39. Ushikubo S, Aoyama T, Kamijo T, et al. Molecular characterization of mitochondrial trifunctional protein deficiency. Am J Hum Genet 1996; 58: 979-88.
40. 40. Indo Y, Yang-Feng TL, Glassberg R, et al. Molecular cloning and nucleotide sequence of cDNA's encoding human long-chain acyl-CoA dehydrogenase and assignment of the location of the gene (ACADL) to chromosome 2. Genomics 1991; 11: 609-20.
41. 41. Matsubara Y, Kraus JP, Yang-Feng TL, et al. Molecular cloning of cDNA's encoding rat and human medium-chain acyl-CoA dehydrogenase and assignment of the gene to human chromosome 1. Proc Natl Acad Sci USA 1986; 83: 6543-7.
42. 42. Kelly DP, Kim J-J, Billadello JJ, et al. Nucleotide sequence of medium-chain acyl-CoA dehydrogenase mRNA and its expression in enzyme-deficient human tissue. Proc Natl Acad Sci USA 1987; 84: 4068-72.
43. 43. Naito E, Ozasa H, Ikeda Y, et al. Molecular cloning and nucleotide sequence of complementary cDNA's encoding human short-chain acyl-CoA dehydrogenase and the study of the molecular basis of short-chainacyl-CoA dehydrogenase deficiency. J Clin Invest 1989; 83: 1605-13.
44. 44. Vredendaal PJCM, van den Berg IET, Malingre HEM, et al. Human short-chain L-3-hydroxy acyl-CoA dehydrogenase: cloning and characterization of the coding sequence. Biochem Biophys Res Commun 1996; 223: 718-23.
45. 45. Kamijo T, Indo Y, Souri M, et al. Medium chain 3-ketoacyl-Coenzyme A thiolase deficiency: a new disorder of fatty acid β-oxidation. Pediatr Res 1997; 42: 569-76.
46. 46. Fukao T, Kamijo K, Osumi T, et al. Molecular cloning and nucleotide sequence of cDNA encoding the entire precursor of rat mitochondrial acetoacetyl-CoA thiolase. J Biochem 1989; 106: 197-204.
47. 47. Kobayashi A, Jiang LL Hashimoto T. Two mitochondrial 3-hydroxyacyl-CoA dehydrogenases in bovine liver. J Biochem 1996; 119: 775-82.
48. 48. Furuta S, Kobayashi A, Miyazama S et al. Cloning and expression of cDNA for a newly identified isozyme of bovine liver 3-hydroxyacyl-CoA dehydrogenase and its import into mitochondria. Biochim Biophys Acta 1997; 1350: 317-24.
49. 49. DiMauro S, DiMauro PMM. Muscle carnitine palmitoyltransferase deficiency and myoglobinuria. Science 1973; 182: 929-31.
50. 50. Taroni F, Verderio E, Dworzak F, et al. Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nature Genet 1993; 4: 314-20.
51. 51. Bonnefont J-P, Taroni F, Cavadini P, et al. Molecular analysis of carnitine palmitoyltransferase II deficiency with hepatomuscular expression. Am J Hum Genet 1996; 58: 971-8.
52. 52. Sue CM, Hirano M, DiMauro S, et al. Neonatal presentations of mitochondrial metabolic disorders. Semin Perinatol 1999; 23: 113-24.
53. 53. Tripp ME, Katcher ML, Peters HA, et al. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathy. N Engl J Med 1981; 305: 385-90.
54. 54. Waber LJ, Valle D, Neill C, et al. Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J Pediatr 1982; 101: 700-4.
55. 55. Treem WR, Stanley CA, Finegold DN, et al. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle and fibroblasts. N Engl J Med 1988; 319: 1331-6.
56. 56. Stanley CA, Deleeuw S, Coates PM, et al. Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol 1991; 30: 709-16.
57. 57. Tein I, DeVivo DC, Bierman F, et al. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy. Pediatr Res 1990; 28: 247-55.
58. 58. Bennett MJ, Hale DE, Pollitt RJ, et al. Endocardial fibroelastosis and primary carnitine deficiency due to a defect in the plasma membrane carnitine transporter. Clin Cardiol 1996; 19: 243-6.
59. 59. Rinaldo P, Stanley CA, Hsu BYL, et al. Sudden neonatal death in carnitine transporter deficiency. J Pediatr 1997; 131: 304-5.
60. 60. Bougneres P-F, Saudubray J-M, Marsac C, et al. Fasting hypoglycemia resulting from hepatic carnitine palmitoyl transferase deficiency. J Pediatr 1981; 98: 742-6.
61. 61. Demaugre F, Bonnefont JP Mitchell G. Hepatic and muscular presentations of carnitine palmitoyl transferase deficiency: two distinct entities. Pediatr Res 1988; 24: 308-11.
62. 62. Falik-Borenstein ZC, Jordan SC, Saudubray J-M, et al. Renal tubular acidosis in carnitine palmitoyltransferase type I deficiency. N Engl J Med 1992; 327: 24-7.
63. 63. Bergman AJIW, Donckerwolcke RAMG, Duran M, et al. Rate-dependent distal renal tubular acidosis and carnitine palmitoyltransferase T deficiency. Pediatr Res 1994; 36: 582-8.
64. 64. IJlst L, Mandel H, Oostheim W, et al. Molecular basis of hepatic carnitine palmitoyltransferase I deficiency. J Clin Invest 1998; 102: 527-31.
65. 65. Stanley CA, Hale DE, Berry GT, et al. A deficiency of carnitine-acylcarnitine translocase in the inner mitochondrial membrane. N Engl J Med 1992; 327: 19-23.
66. 66. Pande SV, Brivet M, Slama A, et al. Carnitine-acylcarnitine translocase deficiency with severe hypoglycemia and auriculoventricular block: translocase assay in permeabilized fibroblasts. J Clin Invest 1993; 91: 1247-52.
67. 67. Brivet M, Slama A, Ogier H, et al. Diagnosis of carnitine -acylcarnitine translocase deficiency by complementation analysis. J Inher Metab Dis 1995; 17: 271-4.
68. 68. Ogier de Baulny H, Slama A, Touati G, et al. Neonatal hyperammonemia caused by a defect of carnitine-acylcarnitine translocase. J Pediatr 1995; 127: 723-8.
69. 69. Demaugre F, Bonnefont J-P, Colonna M, et al. Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. J Clin Invest 1991; 87: 859-64.
70. 70. Hug G, Bove KE Soukup S. Lethal neonatal multiorgan deficiency of carnitine palmitoyltransferase II. N Engl J Med 1991; 325: 1862-4.
71. 71. North KN, Hoppel CL, De Girolami U, et al. Lethal neonatal deficiency of carnitine palmitoyltransferase II associated with dysgenesis of the brain and kidneys. J Pediatr 1995; 127: 414-20.
72. 72. Elpeleg ON, Joseph A, Branski D, et al. Recurrent metabolic decompensation in profound carnitine palmitoyltransferase II deficiency. J Pediatr 1993; 122: 917-9.
73. 73. Verderio E, Cavadini P, Montermini L, et al. Carnitine palmitoyltransferase II deficiency: structure of the gene and characterization of two novel disease-causing mutations. Hum Mol Genet 1995; 4: 19-29.
74. 74. Hale DE, Batshaw M, Coates PM, et al. Long-chain acyl-CoA dehydrogenase deficiency: a cause of non-ketotic hypoglycemia. Pediatr Res 1985; 19: 666-71.
75. 75. Treem WR, Witzleben CA, Piccoli DA, et al. Medium-chain and long-chain acyl-CoA dehydrogenase deficiencies: clinical, pathological and ultrastructural differentiation from Reye's syndrome. Hepatology 1986; 6: 1270-8.
76. 76. Allison F, Bennett MJ, Variend S, et al. Acyl-CoA dehydrogenase deficiency in heart tissue from infants who died suddenly and unexpectedly, with fatty change in liver. Brit Med J 1988; 296: 11-2.
77. 77. Eder M, Krautle F, Dong Y, et al. Characterization of human and pig kidney LCAD and their role in β-oxidation. Eur J Biochem 1997; 245: 600-7.
78. 78. Largilliere C, Vianey-Saban C, Fontaine M, et al. Mitochondrial very long chain acyl-CoA dehydrogenase deficiency - a new disorder of fatty acid oxidation. Arch Dis Child 1995; 73: F103-5.
79. 79. Aoyama T, Uchida Y, Kellet RI, et al. A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase. Biochem Biophys Res Commun 1993; 191: 1369-72.
80. 80. Yamaguchi S, Indo Y, Coates PM, et al. Identification of very-long-chain acyl-CoA dehydrogenase deficiency in three patients previously diagnosed with long-chain acyl-CoA dehydrogenase deficiency. Pediatr Res 1993; 34: 111-3.
81. 81. Strauss AW, Powell CK, Hale DE, et al. Molecular basis of human mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci USA 1995; 92: 10496-500.
82. 82. Souri M, Aoyama T, Orii K, et al. Mutation analysis of very-long-chain acyl-Coenzyme A dehydrogenase (VLCAD) deficiency: identification and characterization of mutant VLCAD cDNA's from four patients. Am J Hum Genet 1996; 58: 97-106.
83. 83. Andresen BS, Olpin S, Poorthuis BJHM, et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet 1999; 64: 479-94.
84. 84. Mathur A, Sims HF, Gopalakrishnan D, et al.Molecular heterogeneity in VLCAD deficiency causing pediatric cardiomyopathy and sudden death. Circulation 1999; 99: 1337-43.
85. 85. Ogilvie I, Pourfarzam M, Jackson S, et al. Very-long -chain acyl-coenzyme A dehydrogenase deficiency presenting as exercise-induced myoglobinuria. Neurology 1994;44: 467-73.
86. 86. Kurtz D, Rinaldo P, Rhead WJ, et al. Targeted disruption of mouse long-chain acyl-CoA dehydrogenase reveals a crucial role in fatty acid oxidation. Proc Natl Acad Sci USA 1998; 95: 15592-7.
87. 87. Tyni T, Pihko H. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Acta Paediatr 1999; 88: 237-45.
88. 88. Wanders RJA, Duran M, IJlst L, et al. Sudden infant death and long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: a new inborn error of fatty acid β-oxidation. Lancet 1989; I: 52-3.
89. 89. Wanders RJA, IJlst L, van Gennip AH, et al. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: identification of a new inborn error of mitochondrial fatty acid β-oxidation. J Inher Metab Dis 1990; 13: 311-4.
90. 90. Hale DE, Thorpe C, Braat K, et al. The L-3-hydoxyacyl-CoA dehydrogenase deficiency. In: Tanaka K, Coates PM, eds. Fatty acid oxidation: clinical, biochemical and molecular aspects. Pp. 503-10. New York: Alan R. Liss, 1990.
91. 91. Jackson S, Bartlett K, Land J, et al. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Pediatr Res 1991; 29: 406-11.
92. 92. Przyrembel H, Jacobs C, IJlst L, et al. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. J Inher Metab Dis 1991; 14: 674-80.
93. 93. Rocchiccioli F, Wanders RJA, Auberg P, et al. Deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase: a cause of lethal myopathy and cardiomyopathy in early childhood. Pediatr Res 1990; 28: 657-62
94. 94. Moore R, Glasgow JFT, Bingham MA, et al. Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency-diagnosis, plasma carnitine fractions and management in a further patient. Eur J Pediatr 1993; 152: 433-6.
95. 95. Dionisi Vici C, Burlina AB, Bertini E, et al. Progressive neuropathy and recurrent myoglobinuria in a child with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. J Pediatr 1991; 118: 744-6.
96. 96. Amirkham R, Timmons C, Brown K, et al. Clinical, biochemical, and morphologic investigations of a case of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Arch Pathol Lab Med 1997; 121: 730-4.
97. 97. Tyni T, Palotie A, Viinikka L, et al. Long-chain 3-hydroxyacyl coenzyme A deficiency with the G1528C mutation: clinical presentation of thirteen patients. J Pediatr 1997; 130: 67-76.
98. 98. Sewell AC, Bender SW, Wirth S, et al. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: a severe fatty acid oxidation disorder. Eur J Pediatr 1994; 153: 745-50.
99. 99. Martins E, Costa A, Silva E, et al. Lethal dilated cardiomyopathy due to long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. J Inher Metab Dis 1996; 19: 373-4.
100. 100. Schrijver-Wieling I, van Rens G, Wittebol-Post D, et al. Retinal dystrophy in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Br J Ophthalmol 1997; 81: 291-4.
101. 101. Pons R, Roig M, Riudor E, et al. The clinical spectrum of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Pediatr Neurol 1996; 14: 236-43.
102. 102. Jackson S, Singh-Kler R, Bartlett K, et al. Combined enzyme defect of mitochondrial fatty acid oxidation. J Clin Invest 1992; 90: 1219-25.
103. 103. Isaacs JJ, Sims HF, Powell CK, et al. Maternal acute fatty liver of pregnancy associated with fetal trifunctional protein deficiency: molecular characterization of a novel maternal mutant allele. Pediatr Res 1996; 40: 393-8.
104. 104. Brackett JC, Sims HF, Rinaldo P, et al. Two a subunit donor splice site mutations cause human trifunctional protein deficiency. J Clin Invest 1995; 95: 2076-82.
105. 105. Orii K, Aoyama T, Wakui K, et al. Genomic and mutational analysis of the mitochondrial trifunctional protein β-subunit (HADHB) gene in patients with trifunctional protein deficiency. Hum Mol Genet 1997; 6: 1215-24.
106. 106. Schaefer J, Jackson S, Dick D, et al. Trifunctional protein deficiency: adult presentation of a usually fatal β-oxidation defect. Ann Neurol 1996; 40: 597-602.
107. 107. Miyajima H, Orii K, Shindo Y, et al. Mitochondrial trifunctional protein deficiency associated with recurrent myoglobinuria in adolescence. Neurology 1997; 49: 833-7.
108. 108. Ibdah JA, Tein I, Dionisi-Vici C, et al. Mild trifunctional protein deficiency is associated with progressive neuropathy and suggests a novel genotype-phenotype correlation. J Clin Invest 1998; 102: 119-9.
109. 109. Wolf JL. Liver disease in pregnancy. Med Clin North Am 1996; 80: 1167-87.
110. 110. Knox TA, Olans LB. Liver disease in pregnancy. New Engl J Med 1996; 335: 569-76.
111. 111. Schoeman MN, Batey RG Wilcken B. Recurrent acute fatty liver of pregnancy associated with a fatty acid oxidation defect in the offspring. Gastroenterology 1991; 100: 544-8.
112. 112. Wilcken B, Leung K-C, Hammond J, et al. Pregnancy and fetal long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Lancet 1993; 341: 407-8.
113. 113. Treem WR, Rinaldo P, Hale DE, et al. Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Hepatol 1994; 19: 339-45.
114. 114. Treem WR, Shoup ME, Hale DE, et al. Acute fatty liver of pregnancy, HELLP, and long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Am J Gastroenterol 1996; 91: 2293-300.
115. 115. Tyni T, Ekholm E Pihko H. Pregnancy complications are frequent in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Am J Obstet Gynecol 1998; 178: 603-8.
116. 116. Strauss AW, Bennett MJ, Rinaldo P, et al. Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Semin Perinatol 1999; 23: 100-12.
117. 117. Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med ( in press).
118. 118. Hicks P, Bennett MJ, Squires J, et al. Heterozygosity for long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and deteriorating liver function in an HIV-infected newborn. J Pediatr 1995; 127: 599-602.
119. 119. Divry P, David M, Gregersen N, et al. Dicarboxylic aciduria due to medium-chain acyl-CoA Dehydrogenase defect. A cause of hypoglycemia in childhood. Acta Paediatr Scand 1983; 72: 943-9.
120. 120. Stanley CA, Hale DE, Coates PM, et al. Medium-chain acyl-CoA dehydrogenase deficiency in children with non-ketotic hypoglycemia and low carnitine levels. Pediatr Res 1983; 17: 877-84.
121. 14C ]octanoate oxidation and medium-chain acyl-CoA dehydrogenase in fibroblasts. Science 1983; 221: 73-5.
122. 122. Iafolla AK, Thompson RJJ Roe CR. Medium-chain acylcoenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 1994; 124: 409-15.
123. 123. Howat AJ, Bennett MJ, Shaw L, et al. Deficiency of medium-chain acyl-CoA dehydrogenase presenting as sudden infant death syndrome. Br Med J 1984; 288: 976.
124. 124. Howat AJ, Bennett MJ, Variend S, et al. Defects of metabolism of fatty acids in the sudden infant death syndrome. Br Med J 1985; 290: 1771-3.
125. 125. Duran M, Hofkamp M, Rhead WJ et al. Sudden child death and "healthy" affected members with medium-chain acyl-CoA dehydrogenase deficiency. Pediatrics 1986; 78: 1052-7.
126. 126. Roe CR, Millington DS, Maltby DA, et al. Recognition of medium-chain acyl-CoA dehydrogenase deficiency in asymptomatic siblings of children dying of sudden infant death or Reye-like syndromes. J Pediatr 1986; 108: 13-8.
127. 127. Blakemore AIF, Singleton H, Pollitt RJ, et al. Frequency of the G985 MCAD mutation in the general population. Lancet 1991; 337: 298-9.
128. 128. Matsubara Y, Narisawa K, Tada K, et al. Prevalence of K329E mutation in medium-chain acyl-CoA dehydrogenase gene determined from Guthrie cards. Lancet 1991; 338: 552-3.
129. 129. Kolvraa S, Gregersen N, Blakemore AIF, et al. The most common mutation causing medium-chain acyl-CoA dehydrogenase deficiency is strongly associated with a particular haplotype in the region of the gene. Hum Genet 1991; 87: 425.
130. 130. Matsubara Y, Narisawa K, Miyabayashi S, et al. Identification of a common mutation in patients with medium-chain acyl-CoA dehydrogenase deficiency. Biochem Biophys Res Commun 1990; 171: 498-505.
131. 131. Kelly DP, Whelan AJ, Ogden ML, et al. Molecular characterization of inherited medium-chain acyl-CoA dehydrogenase deficiency. Proc Natl Acad Sci USA 1990; 87: 9236-40.
132. 132. Chase DH, Hillman SL, Van Hove JKL, et al. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997; 43: 2106-13.
133. 133. Ziadeh R, Hoffman EP, Finegold DN, et al. Medium-chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows a high incidence and unexpected mutation frequencies. Pediatr Res 1995; 37: 675-8.
134. 134. Amendt BA, Greene C, Sweetman L, et al. Short-chain acyl-CoA dehydrogenase deficiency. Clinical and biochemical studies in two patients. J Clin Invest 1987; 79: 1303-9.
135. 135. Coates PM, Hale DE, Finocchiaro G, et al. Genetic deficiency of short-chain acyl-coenzyme A dehydrogenase in cultured fibroblasts from a patient with muscle carnitine deficiency and severe skeletal muscle weakness. J Clin Invest 1988; 81: 171-5.
136. 136. Sewell AC, Herwig J, Bohles H, et al. A new case of short-chain acyl-CoA dehydrogenase deficiency with isolated ethylmalonic aciduria. Eur J Pediatr 1993; 152: 922-4.
137. 137. Dawson DB, Waber L, Hale DE, et al. Transient organic aciduria and persistent lacticacidemia in a patient with short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 1995; 126: 69-71.
138. 138. Baerlocher KE, Steinmann B, Aguzzi A, et al. Short-chain acyl-CoA dehydrogenase deficiency in a 16-year-old girl with severe muscle wasting and scoliosis. J Inher Metab Dis 1997; 20: 427-31.
139. 139. Bhala A, Willi SM, Rinaldo P, et al. Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 1995; 126: 910-5.
140. 140. Gregersen N, Winter VS, Corydon MJ, et al. Identification of four new mutations in the short-chain acyl-CoA dehydrogenase gene in two patients: one of the variant alleles, 511C to T, is present at an unexpectedly high frequency in the general population, as was the case for 625G to A, together conferring susceptibility to ethylmalonic aciduria. Hum Mol Genet 1998; 7: 619-27.
141. 141. Corydon MJ, Gregersen N, Lehnert W, et al. Ethylmalonic aciduria is associated with an amino acid variant of short-chain acyl-CoA dehydrogenase. Pediatr Res 1996; 39: 1059-66.
142. 142. AI Odaib A, Schneider BL, Bennett MJ, et al. A defect in the transport of long-chain fatty acids associated with acute liver failure. N Engl J Med 1998; 339: 1752-7.
143. 143. Tein I, De Vivo DC, Hale De, et al. Short-chain L 3-hydroxyacyl-CoA dehydrogenase deficiency in muscle: a new cause of recurrent myoglobinuria and encephalopathy. Ann Neurol 1991; 30: 415-9.
144. 144. Bennett MJ, Weinberger MJ, Kobori JA, et al. Mitochondrial short-chain L 3-hydroxybutyryl-CoA dehydrogenase deficiency: a new defect of fatty acid oxidation. Pediatr Res 1996; 39: 185-8.
145. 145. Bennett MJ, Spotswood SD, Ross KF, et al. Fatal hepatic short-chain L 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical, biochemical and pathological studies on three subjects with this recently identified disorder of mitochondrial β-oxidation. Pediatr Dev Pathol 1999; in press.
146. 146. Kamijo T, Indo I, Souri M, et al. Medium-chain 3-ketoacyl-CoA thiolase deficiency: a new disorder of mitochondrial fatty acid β-oxidation. Pediatr Res 1997; 42: 569-76.
147. 147. Roe CR, Millington DS, Norwood DL, et al. 2,4-Dienoyl-coenzyme A reductase deficiency: a possible new disorder of fatty acid oxidation. J Clin Invest 1990; 85: 1703.
148. 148. Sweetman L, Williams JC. Branched chain organic acidurias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 7th ed. Pp. 1387-1422. New York: McGraw-Hill, 1995.
149. 149. Thompson GN, Hsu BYL, Pitt JJ, et al. Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med 1997; 337: 1203-7.
150. 150. Bennett MJ. The laboratory diagnosis of inborn errors of fatty acid oxidation. Ann Clin Biochem 1990; 27: 519-31.
151. 151. Rinaldo P, O'Shea JJ, Coates PM, et al. Medium-chain acyl-CoA dehydrogenase deficiency: diagnosis by stable isotope dilution analysis of urinary n-hexanoylglycine and 3-phenylpropionylglycine. N Engl J Med 1988; 319: 1308-13.
152. 152. Millington DS, Terada N, Chase DH, et al. The role of tandem mass spectrometry in the diagnosis of fatty acid oxidation disorders. In: Coates PM, Tanaka K, eds. New developments in fatty acid oxidation. Pp. 339-54. New York: Wiley-Liss, 1992.
153. 153. Pollitt RJ. Clinical and biochemical presentations in 20 cases of hydroxydicarboxylic aciduria. In: Tanaka K, Coates PM, eds. Fatty acid oxidation: clinical, biochemical and molecular aspects. Pp. 495-502. New York: AR Liss, 1990.
154. 154. Bennett MJ, Sherwood WG, Gibson KM, et al. Secondary inhibition of multiple NAD-requiring dehydrogenase enzymes in respiratory chain complex I deficiency: possible metabolic markers for the primary defect. J Inher Metab Dis 1993; 16: 560-2.
155. 155. Bennett MJ, Weinberger MJ, Sherwood WG, et al. Secondary 3-hydroxydicarboxylic aciduria mimicking long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. J Inher Metab Dis 1994; 17: 283-6.
156. 156. Saudubray J-M, Coude F-X, Demaugre F, et al. Oxidation of fatty acids in cultured fibroblasts: a model system for the detection and study of defects in oxidation. Pediatr Res 1982; 16: 877-81.
157. 157. Rhead WJ. Screening for inborn errors of fatty acid oxidation in cultured fibroblasts: an overview. In: Tanaka K, Coates PM, eds. Fatty acid oxidation: clinical, biochemical and molecular aspects. Pp. 365-82. New York: AR Liss, 1990.
158. 158. Manning NJ, Olpin SE, Pollitt RJ, et al. A comparison of [9,10-3H] palmitic and [9,10-3H] myristic acids for the detection of fatty acid oxidation defects in intact cultured fibroblasts. J Inher Metab Dis 1990; 13: 58-68.
159. 159. Nada MA, Chace DH, Sprecher H, et al. Investigation of β-oxidation intermediates in normal and MCAD-deficient human fibroblasts using tandem mass spectrometry. Biochem Mol Med 1995; 54: 59-66.
160. 160. Schmidt-Sommerfeld E, Bobrowski PJ, Penn D, et al. Analysis of carnitine esters by radio high-performance liquid chromatography in cultured skin fibroblasts from patients with mitochondrial fatty acid oxidation disorders. Pediatr Res 1998; 44: 210-4.
161. 161. Lehman TC, Hale DE, Bhala A, et al. An acyl-coenzyme A dehydrogenase assay utilizing the ferricenium ion. Anal Biochem 1990; 186: 280-4.
162. 162. Hale DE, Cornell JE, Bennett MJ. Stability of long-chain and short-chain 3-hydroxyacyl-CoA dehydrogenase activity in post-mortem liver. Clin Chem 1997; 43: 273-8.
163. 163. Bennett MJ, Allison F, Pollitt RJ, et al. Fatty acid oxidation disorders as causes of unexpected death in infancy. Prog Clin Biol Res 1990; 321: 349-66.
164. 164. Bennett MJ, Powell S. Metabolic disease and sudden unexpected death in infancy. Hum Pathol 1994; 25: 742-6.
165. 165. Boles RG, Martin SK, Blitzer MG, et al. Biochemical diagnosis of fatty acid oxidation disorders by metabolite analysis of post-mortem liver. Hum Pathol 1994; 25: 735-41.
166. 166. Boles RG, Buck EA, Blitzer MG, et al. Retrospective biochemical screening of fatty acid oxidation disorders in post mortem liver of 418 cases of sudden unexpected death in the first year of life. J Pediatr 1998; 132: 924-33.
167. 167. Rinaldo P, Yoon HR, Yu C, et al. Sudden and unexpected neonatal death: a protocol for the post mortem diagnosis of fatty acid oxidation disoders. Semin Perinatol 1999; 23: 204-10.
168. 168. Rashed MS, Ozand PT, Bennett MJ, et al. Fatty acid oxidation disorders and sudden death: diagnosis of inborn errors of metabolism in sudden death cases by acylcarnitine analysis of post mortem bile. Clin Chem 1995; 41: 1109-14.